Design, Synthesis and Evaluation of 2,4-Diaminoquinazoline Derivatives as Potential Tubulin Polymerization Inhibitors. 2020

Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, 04510, Mexico.

Microtubules are highly dynamic polymers composed of α- and β-tubulin proteins that have been shown to be potential therapeutic targets for the development of anticancer drugs. Currently, a wide variety of chemically diverse agents that bind to β-tubulin have been reported. Nocodazole (NZ) and colchicine (COL) are well-known tubulin-depolymerizing agents that have close binding sites in the β-tubulin. In this study, we designed and synthesized a set of nine 2,4-diaminoquinazoline derivatives that could occupy both NZ and COL binding sites. The synthesized compounds were evaluated for their antiproliferative activities against five cancer cell lines (PC-3, HCT-15, MCF-7, MDA-MB-231, and SK-LU-1), a noncancerous one (COS-7), and peripheral blood mononuclear cells (PBMC). The effect of compounds 4 e and 4 i on tubulin organization and polymerization was analyzed on the SK-LU-1 cell line by indirect immunofluorescence, western blotting, and tubulin polymerization assays. Our results demonstrated that both compounds exert their antiproliferative activity by inhibiting tubulin polymerization. Finally, a possible binding pose of 4 i in the NZ/COL binding site was determined by using molecular docking and molecular dynamics (MD) approaches. To our knowledge, this is the first report of non-N-substituted 2,4-diaminoquinazoline derivatives with the ability to inhibit tubulin polymerization.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
September 2019, Chemical biology & drug design,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
September 2017, Molecules (Basel, Switzerland),
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
January 2023, Assay and drug development technologies,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
July 2021, Bioorganic chemistry,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
March 2011, Bioorganic & medicinal chemistry letters,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
March 2017, ChemMedChem,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
August 2020, Bioorganic & medicinal chemistry letters,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
November 2023, Future medicinal chemistry,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
December 2018, Investigational new drugs,
Frida S Herrera-Vázquez, and Félix Matadamas-Martínez, and Rodrigo Aguayo-Ortiz, and Laura Dominguez, and Teresa Ramírez-Apan, and Lilián Yépez-Mulia, and Francisco Hernández-Luis
March 2023, Zeitschrift fur Naturforschung. C, Journal of biosciences,
Copied contents to your clipboard!